Please use this identifier to cite or link to this item:
Title: Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells
Authors: Chien W. 
Ding L.-W. 
Sun Q.-Y. 
Torres-Fernandez L.A.
Tan S.Z.
Xiao J. 
Lim S.L. 
Garg M. 
Lee K.L. 
Kitajima S. 
Takao S. 
Leong W.Z. 
Sun H.
Tokatly I.
Poellinger L. 
Gery S.
Koeffler P.H. 
Keywords: IRE1?
Pancreatic cancer
Issue Date: 2014
Publisher: Impact Journals LLC
Citation: Chien W., Ding L.-W., Sun Q.-Y., Torres-Fernandez L.A., Tan S.Z., Xiao J., Lim S.L., Garg M., Lee K.L., Kitajima S., Takao S., Leong W.Z., Sun H., Tokatly I., Poellinger L., Gery S., Koeffler P.H. (2014). Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells. Oncotarget 5 (13) : 4881-4894. ScholarBank@NUS Repository.
Abstract: Endoplasmic reticulum stress from unfolded proteins is associated with the proliferation of pancreatic tumor cells, making the many regulatory molecules of this pathway appealing targets for therapy. The objective of our study was to assess potential therapeutic efficacy of inhibitors of unfolded protein response (UPR) in pancreatic cancers focusing on IRE1? inhibitors. IRE1?-mediated XBP-1 mRNA splicing encodes a transcription factor that enhances transcription of chaperone proteins in order to reverse UPR. Proliferation assays using a panel of 14 pancreatic cancer cell lines showed a dose- and time-dependent growth inhibition by IRE1?-specific inhibitors (STF-083010, 2-Hydroxy-1-naphthaldehyde, 3-Ethoxy-5,6-dibromosalicylaldehyde, toyocamycin). Growth inhibition was also noted using a clonogenic growth assay in soft agar, as well as a xenograft in vivo model of pancreatic cancer. Cell cycle analysis showed that these IRE1? inhibitors caused growth arrest at either the G1 or G2/M phases (SU8686, MiaPaCa2) and induced apoptosis (Panc0327, Panc0403). Western blot analysis showed cleavage of caspase 3 and PARP, and prominent induction of the apoptotic molecule BIM. In addition, synergistic effects were found between either STF-083010, 2-Hydroxy-1-naphthaldehyde, 3-Ethoxy-5,6-dibromosalicylaldehyde, or toyocamycin and either gemcitabine or bortezomib. Our data suggest that use of an IRE1? inhibitor is a novel therapeutic approach for treatment of pancreatic cancers.
Source Title: Oncotarget
ISSN: 19492553
DOI: 10.18632/oncotarget.2051
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Selective inhibition of unfolded protein.pdf1.85 MBAdobe PDF



Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.